Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

Affiliations

L E Ramsay et al. Lancet. 1996.

. 1996 Aug 10;348(9024):387-8.

doi: 10.1016/s0140-6736(96)05516-x.

¹ Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK.

Erratum in

The Sheffield table for primary prevention of coronary heart disease: corrected.
Ramsay LE, Haq IU, Jackson PR, Yeo WW. Ramsay LE, et al. Lancet. 1996 Nov 2;348(9036):1251. doi: 10.1016/s0140-6736(05)65536-5. Lancet. 1996. PMID: 8898071 No abstract available.

No abstract available

Sheffield risk and treatment table for primary prevention of coronary heart disease.
Wierzbicki AS, Reynolds TM. Wierzbicki AS, et al. Lancet. 1996 Oct 12;348(9033):1039-40; author reply 1040-1. doi: 10.1016/s0140-6736(05)64975-6. Lancet. 1996. PMID: 8855895 No abstract available.
Sheffield risk and treatment table for primary prevention of coronary heart disease.
Chamberlan JC, Fraser WD. Chamberlan JC, et al. Lancet. 1996 Oct 12;348(9033):1040; author reply 1040-1. doi: 10.1016/s0140-6736(05)64977-x. Lancet. 1996. PMID: 8855896 No abstract available.
Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines.
Jones AF. Jones AF. Lancet. 1997 Oct 18;350(9085):1174-5. doi: 10.1016/s0140-6736(05)63818-4. Lancet. 1997. PMID: 9343523 No abstract available.